
Few women with invasive breast cancer who are treated with lumpectomy, radiation and five years of tamoxifen would benefit from taking an aromatase inhibitor after tamoxifen.  "After looking at all the factors of the women in this retrospective study, we believe the addition of an aromatase inhibitor to the five years of tamoxifen for all patients would result in only a 1 to 2 percent clinical benefit," explained Gary Freedman, M.D.  

